Capital World Investors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Capital World Investors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,457,280	Closed	-$42.7M	–	629
2021 Q4	$42.7M	Sell	1,457,280 -612	-0%	-$19K	0.01%	459
2021 Q3	$37.1M	Buy	1,457,892 +782	+0.1%	+$23K	0.01%	486
2021 Q2	$51M	Buy	1,457,110 +720	+0%	+$28.1K	0.01%	449
2021 Q1	$59.3M	Buy	1,456,390 +1,781	+0.1%	+$81.9K	0.01%	417
2020 Q4	$63M	Buy	1,454,609 +1,188	+0.1%	+$58.6K	0.01%	388
2020 Q3	$80.1M	Buy	1,453,421 +826	+0.1%	+$52.5K	0.02%	353
2020 Q2	$91.7M	Buy	1,452,595 +147	+0%	+$10.1K	0.02%	313
2020 Q1	$74.2M	Buy	1,452,448 +984,928	+211%	+$66M	0.02%	297
2019 Q4	$37.2M	Buy	467,520 +87,520	+23%	+$5.19M	0.01%	369
2019 Q3	$18.4M	Buy	380,000 +220,000	+138%	+$11.5M	﹤0.01%	416
2019 Q2	$8.42M	Hold	160,000	–	–	﹤0.01%	495
2019 Q1	$8.47M	Hold	160,000	–	–	﹤0.01%	488
2018 Q4	$6.57M	Hold	160,000	–	–	﹤0.01%	488
2018 Q3	$6.08M	Hold	160,000	–	–	﹤0.01%	526
2018 Q2	$7.23M	Hold	160,000	–	–	﹤0.01%	507
2018 Q1	$7.73M	Buy	+160,000	New	+$8.92M	﹤0.01%	482

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital World Investors's GBT Position: Q1 2022 in Review

Capital World Investors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 1,457,280 shares — an estimated $42.7M sold.

Capital World Investors first reported a position in GBT in Q1 2018 and held it in 16 quarters. The position peaked at $91.7M in Q2 2020. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

Capital World Investors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Capital World Investors sold 1,457,280 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $42.7M.
Capital World Investors first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 16 quarters.
Capital World Investors's Global Blood Therapeutics, Inc. position peaked at $91.7M in Q2 2020.
204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Capital World Investors's 13F filing for Q1 2022, filed 16 May 2022.